Effektivnost' trekhkomponentnoy terapii s ispol'zovaniem liraglutida (Viktoza) -pervogo analoga glyukagonopodobnogo peptida-1 dlitel'nogo deystviya - u patsientov s sakharnym diabetom 2 tipa i vistseral'nym ozhireniem


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Pathogenetic link between type 2 diabetes mellitus (DM2) and obesity is proved. Both diabetes and obesity increase the risk of cardiovascular disease, which are the major cause of premature death DM2. Modern scientific research allowed to thoroughly examine the role of adipocytokines in the regulation of the metabolism of carbohydrates and fats in the human body and their changes during therapy with modern drugs used in the treatment of DM2 in obese patients. The data on the effectiveness of glycemic control and correction of visceral obesity during the treatment with liraglutide in combination with oral antidiabetic drugs in patients with DM2 and obesity are presented.

Full Text

Restricted Access

About the authors

M. B Antsiferov

O. M Koteshkova

Email: koala58@mail.ru

References

  1. Smyth S., Heron A. Diabetes and obesity: the twin epidemics. Nat. Med. 2006;12:75-80.
  2. Coronary heart disease: reducing the risk. The scientific background for primary and secondary prevention of coronary heart disease. A worldwide view. Intern. Atheroscler. Soc. Nutr. Metab. Cardiovasc. Dis. 1998;8:205-71.
  3. Wing R.R., Lang W., Wadden T.A., Safford M., Knowler W.C., Bertoni A.G., Hill J.O., Brancati F.L., Peters A., Wagenknecht L.; the Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-86.
  4. Monti V., Carlson J.J., Hunt S.C., Adams T.D. Relationship of ghrelin and leptin hormones with body mass index and waist circumference in a random sample of adults. J. Am. Diet. Assoc. 2006;106(6):822-28.
  5. Davis J.F., Choi D.L., Benoit S.C. Insulin, leptin and reward. Trends in Endocrinology and Metabolism. 2010;21(2):68-74.
  6. Morton G.J., Schwartz M.W. Leptin and the CNS control of glucose metabolism. Physiol. Rev. 2011;91(2):389-411.
  7. Ye R., Holland W.L., Gordillo R., Wang M., Wang Q.A., Shao M., Morley T.S., Gupta R.K., Stahl A., Scherer P.E. Adiponectin is essential for lipid homeostasis and survival under insulin deficiency and promotes в-cell regeneration. eLife. 2014;3. doi: 10.7554/eLife.03851.
  8. Harwood H.J. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology. 2012;63:57-75.
  9. Rao J.R., Keating D.J., Chen C., Parkington H.C. Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARг-dependent and PPARг-independent mechanisms. Diabetes Obes. Metab. 2012;14(11):983-89
  10. Tishinsky J.M., Robinson L.E., Dyck D.J. Insulin-sensitizing properties of adiponectin. Biochimie. 2012;94(10):2131-36.
  11. Falcm-Pires I., Castro-Chaves P., Miranda-Silva D., Louren3o A.P., Leite-Moreira A.F. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov. Today. 2012;17:880-89.
  12. Wolfson N., Gavish D., Matas Z., Boaz M., Shargorodsky M. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load. Exp. Diabetes Res. 2012;2012:250621.
  13. Cho Y.M., Fujita Y., Kieffer T.J. Glucagon-like peptide-1: glucose homeostasis and beyond. Rev. Physiol. 2014;76:535-59.
  14. Doyle M.E., Egan J.M. Mechanisms of action of GLP-1 in the pancreas. Pharmacol. Ther. 2007;113(3):546-93.
  15. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986;63:492-98.
  16. Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P., Andersen D.K., Elahi D. The extra-pancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 2009;94(6):1843-52.
  17. Opinto G, Natalicchio A., Marchetti P. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. Arch. Physiol Biochem. 2013;119(4):170-78.
  18. Hayes M.R., Skibicka K.P., Grill H.J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like peptide-1 receptor stimulation. Endocrinology. 2008;149:4059-68.
  19. Larsen P.J. Mechanisms behind GLP-1 induced weight loss. Br. J. Diabetes Vasc. Dis. 2008;8(2):S34-41.
  20. Jelsing J., Vrang N., Hansen G., Raun K., Tang-Christensen M, Bjerre Knudsen L. Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes Obes. Metab. 2012;14:531-38.
  21. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M, Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72.
  22. Chelikani P.K., Haver A.C., Reidelberger R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005;288(7): R1695-706.
  23. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes. 2006;55(12):3387-93.
  24. Meier J.J., Gethmann A., Gotze O., Gallwitz B., Holst J.J., Schmidt W.E., Nauck M.A. Glucagonlike peptide 1 (GLP-1) abolishes the postprandial rise in triglyceride concentrations and lowers free fatty acid levels in humans. Diabetology. 2006;9(3):452-58.
  25. Deacon C.F., Ahmn B. Physiology of incre tins in health and disease. Rev. Diabet. Stud. 2011;8(3):293-306.
  26. Vilsboll T., Krarup T, Madsbad S., Holst J.J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002; 45:1111-19.
  27. Niswender K., Pi-Sunyer X., Buse J., Jensen K.H., Toft A.D., Russell-Jones D., Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes. Metab. 2013;15:42-54.
  28. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E, Brett J.H., Zychma M., Blonde L.; LEAD-6 Study Group.Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
  29. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P.M., Zdravkovic M., Bode B.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-81.
  30. Marre M., Shaw J., Brandle M, Bebakar W.M., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycae-mic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 2009;26:268-78.
  31. Nauck M, Frid A., Hermansen K., Shah N.S., Tankova T, Mitha I.H., Zdravkovic M., Dbring M., Matthews D.R.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiri-de, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
  32. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., Thomsen A.B., Swndergaard R.E., Davies M.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-56.
  33. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., Zdravkovic M., Ravn G.M., Simy R.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-55.
  34. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-30.
  35. Buse J.B., Sesti G., Schmidt W.E., Montanya E., Chang C.T., Xu Y, Blonde L., Rosenstock J.; Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves gly-cemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010; 33:1300-303.
  36. Inoue K., Maeda N., Kashine S., Fujishima Yu., Kozawa J., Hiuge-Shimizu A., Okita K., Imagawa A., Funahashi T., Shimomura I. Shortterm effects of liraglutide on visceral fat adiposity, appetite, and food preference. Cardiovasc Diabetol. 2011;10(109):1-8.
  37. Horowitz M., Flint A., Jones K.L., Hindsberger C., Rasmussen M.F., Kapitza C., Doran S., Jax T., Zdravkovic M., Chapman I.M. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res. Clin. Pract. 2012;97:258-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies